Market Research Logo

Rosacea - Pipeline Review, H2 2015

Introduction
Global Markets Direct Report Coverage
Rosacea Overview
Therapeutics Development
Pipeline Products for Rosacea - Overview
Rosacea - Therapeutics under Development by Companies
Rosacea - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Rosacea - Products under Development by Companies
Rosacea - Companies Involved in Therapeutics Development
Allergan Plc
Amorepacific Corporation
Delenex Therapeutics AG
Dermira Inc.
Foamix Pharmaceuticals Ltd.
Hovione FarmaCiencia SA
Merz Pharma GmbH & Co. KgaA
Promius Pharma, LLC
TWi Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Rosacea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles AC-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACUD-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DFD-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DLX-1008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DRM-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FMX-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxymetazoline hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDI-320 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SIG-990 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tetracycline MR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rosacea - Recent Pipeline Updates
Rosacea - Dormant Projects
Rosacea - Discontinued Products
Rosacea - Product Development Milestones
Featured News & Press Releases
Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea
Apr 07, 2015: Dr. Reddy’s Laboratories and its subsidiary Promius Pharma announce the filing of NDA with the USFDA For DFD-09
Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK
Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission
Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea
Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso
Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33%
Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso
Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
Mar 16, 2012: Galderma Completes Phase III Trials Of Investigational Drug Targeting Facial Erythema Of Rosacea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Rosacea, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Rosacea - Pipeline by Allergan Plc, H2 2015
Rosacea - Pipeline by Amorepacific Corporation, H2 2015
Rosacea - Pipeline by Delenex Therapeutics AG, H2 2015
Rosacea - Pipeline by Dermira Inc., H2 2015
Rosacea - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2015
Rosacea - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015
Rosacea - Pipeline by Promius Pharma, LLC, H2 2015
Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2015
Rosacea - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Rosacea Therapeutics - Recent Pipeline Updates, H2 2015
Rosacea - Dormant Projects, H2 2015
Rosacea - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Rosacea, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Rosacea - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Rosacea - Pipeline Review, H2 2015’, provides an overview of the Rosacea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Rosacea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Rosacea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Rosacea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;